SENSEONICS HOLDINGS INC. news, videos and press releases
For more news please use our advanced search feature.
SENSEONICS HOLDINGS INC. - More news...
SENSEONICS HOLDINGS INC. - More news...
- Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference
- Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time
- Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
- Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting
- Senseonics Holdings, Inc. Provides Update on Eversense 365 Launch
- Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
- Senseonics Holdings, Inc. Reports Third Quarter 2024 Financial Results
- Senseonics Holdings, Inc. Announces $16 Million Registered Direct Offering
- Senseonics Holdings, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for November 7, 2024 at 4:30 P.M. Eastern Time
- Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System
- Mercy Places First Commercial Eversense 365: The World’s First and Only 365-Day Continuous Glucose Monitor
- Eversense 365 Receives FDA Clearance: The World’s First One Year CGM
- Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference
- Thinking about buying stock in Senseonics Holdings, Ainos, Marpai, Rush Street Interactive, or Evgo?
- Senseonics Holdings, Inc. Reports Second Quarter 2023 Financial Results
- Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time
- Senseonics Announces Equity Grants To Employees Under Inducement Plan
- New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions
- Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes
- Senseonics to Participate in the Jefferies Healthcare Conference
- Senseonics Holdings, Inc. Reports First Quarter 2023 Financial Results
- Senseonics Holdings, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 9, 2023, at 4:30 p.m. Eastern Time
- Senseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial
- Senseonics Announces Equity Grants To Employees Under Inducement Plan
- Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
- Senseonics Holdings, Inc. and PHC Holdings Corporation To Host Joint Eversense CGM Virtual Analyst and Investor Event on March 15, 2023
- Senseonics Announces Equity Grants To Employees Under Inducement Plan
- Senseonics to Present at the Stifel 2022 Healthcare Conference
- Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results
- Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM)
